Применение пероральных и парентеральных препаратов железа у пациентов с тяжелыми формами железодефицитной анемии

А. В. Зайченко; Д. В. Лыткин

doi:10.18370/2309-4117.2015.24.30-36

Authors

А. В. Зайченко National University of pharmacy, Kharkiv, Ukraine
Д. В. Лыткин National University of pharmacy, Kharkiv, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.24.30-36

Keywords:

iron deficiency anemia, oral iron preparations, parenteral iron preparations, Venofer®

Abstract

Treatment of iron deficiency anemia include the elimination of the root causes of iron loss (liquidation hemorrhage, treatment of major diseases), diet rich in heme and iron, and use of mono- or combination preparations of iron.

For initial treatment of iron deficiency are used oral ferrous drugs, which contain iron in the bivalent (ionic) or trivalent (non-ionic) form.

In emergency conditions where oral iron preparations cannot quickly recover iron deficiency, iron preparations are administered parenteral, and preferred dosage form is intravenous administration.

Numerous clinical studies have shown that the drug Venofer® (iron sucrose (III)) for intravenous administration is more effectively restore hematocrit level, serum ferritin and erythropoiesis than other parenteral and oral iron preparations.

Author Biographies

А. В. Зайченко, National University of pharmacy, Kharkiv

MD, professor, head of the Department of Clinical Pharmacology of the Institute of qualification improvement for NUPh pharmacy specialists

Д. В. Лыткин, National University of pharmacy, Kharkiv

Post-graduate student of the Department of Clinical Pharmacology of the Institute of qualification improvement for NUPh pharmacy specialists

References

Anastasevich, L.A., Malcoch, A.V. “Iron deficiency anemia in infants and young children.” Attending Physician, 7(2006): published online. Last accessed Sept 06, 2015.
R ecommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep, 47 (RR-3) (1998): 1–29.
Gorodetsky, V.V., Godulyan, O.V. Iron deficiency and iron deficiency anemia: diagnostics and treatment (Methodical recommendations). Moscow. Medpractice-M (2006): 28 p.
Dvoretsky, L.I. “Hypochromic anemia.” Gematology, 9 (Vol. 3) (2001).
Zakharova, I.N., Dmitrieva, Y.A. “The syndrome of anemia in pediatric practice: differential diagnosis and therapy.” Effective Pharmacotherapy. Pediatrics, 3(2011): 40–47.
Kaye, P., Abdullah, K., Wood, J., James, P., et al. “Iron-induced pathology of upper gastrointestinal tract: characteristic observation in patients receiving oral iron therapy.” Health of Ukraine, 1(13) (2014): 20–22.
Kolosova, N.G. “Iron deficiency anemia in infants.” Pediatrics, 04(2013): published online. Last accessed Sept 06, 2015.
Okorokov, A.N. Diagnostics of internal organs diseases. Vol. 4. Diagnostics of blood system diseases. Moscow. Medical literature (2001): 512 p.
Sarsania, S.I., Tikhomirov, A.L., Nochevkin, E.V., Touskaev, K.S. “Nuances of diagnostics and treatment of iron deficiency anemia.” Difficult Patient, 02(2012): published online. Last accessed Sept 06, 2015.
Sokur, T.N., Dubrovina, N.V., Fedorova, Y.V. “The principles of prevention and treatment of iron deficiency anemia in pregnant women.” Consilium medicum, 2 (Vol. 9) (2007).
Tarasova, I.S. “Iron deficiency anemia in children and adolescents.” Current Pediatrics Issues, 2(10) (2011): 40–48.
Tatvidze, M.L., Khvedelidze, V.A. “Impact of nutritional factors on the development of iron deficiency.” Herald SEUA , “Chemical and environmental technology”. 2 (Issue 15) (2012).
Tikhomirov, A.L., Sarsania, S.I., Nochevkin, E.V. “Some aspects of diagnostics and treatment of iron deficiency states in practice at the present stage.” Difficult Patient, 11(2011): published online. Last accessed Sept 06, 2015.
Tsvetkova, O.A. “Medical and social aspects of iron deficiency anemia.” Russian Medical Journal, 5(2009): 387–391.
Shalina, R.I., Kutakova, Y.Y., Breusenko, L.I., et al. “Assessment of the effectiveness of the drug Venofer in iron deficiency states after obstetric hemorrhage.” Questions of Gynecology, Obstetrics and Perinatology, 1(3) (2004): 37–42.
Fisher, A.E.O., Naughton, D.P. “Iron supplements: the quick fix with long-term consequences.” Nutr J, 3(2) (2004).
A ronoff, G.R., Bennett, W.M., Blumenthal, S., Charytan, C., et al. “Iron sucrose in hemodialysis patients: Safety and efficacy of iron replacement and maintenance therapy.” Kidney Int, 66(2004):1193–1198.
A uerbach, M., Ballard, H., Glaspy, J. et al. “Clinical update: intravenous iron for anaemia.” Lancet, 369(2007): 1502–1504.
Beshara, S., Lundqvist, H., Sundin, J., et al. Pharmacokinetic analysis and red cell utilization of 52Fe/59Fe labelled iron (III) hydroxide sucrose complex following intravenous administration using positron emission tomography. Clinical study report (1997). American Regent, Inc. Shirley. New York.
Bodnar, L.M., Scanlon, K.S., Freedman, D.S., et al. “High prevalence of postpartum anemia among low income women in the United States.” American Journal of Obstetrics and Gynecology, 185(2001): 438–443.
C harytan, C., Quinibi, W., Bailie, W. “Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on Dialysis.” Nephron Clin Pract, 100(2005): 55–62.
E uropean Parliament. “Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use.” Official Journal L, 136(47) (2004): 34–57.
Heath, A.L., Fairweather-Tait, S.J. “Clinical implications of changes in the modern diet: iron intake, absorbtion and status.” Best Practical & Reasearch Clin Haem, 2 (Vol. 15) (2002): 225–241.
Instructions for use of the drug Venofer®.
W orld Health Organization. Iron deficiency anemia assessment, prevention and control. A guid for programme managers. Geneva. WHO (2001). [http:// www.who.int/nutrition/publications/en/ida_assessment_ prevention_control.pdf], last accessed Sept 9, 2015.
M acdougall, I., Bailie, G., Richardson, D., Tanner, J., Gagnon, S.P. “Worldwide safety profile of iron sucrose injection (Venofer): analysis of 1,044,477 patients from 1992 to 2001.” J Am Soc Nephrol, 12(2001): 333A.
R evised European Best Practice Guidelines for the Management of anemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant, 19 (Suppl. 2) (2004): 2–45.
R ogler, G., Vavricka, S. “Anemia in inflammatory bowel disease: an under-estimated problem?” Front Med Lausanne, 1(2015): 58.
R ottembourg, J., Kadri, A., Leonard, E., et al. “Do two intravenous iron sucrose preparations have the same efficacy?” Nephrol Dial Transplant, 26(10) (2011): 3262–3267.
Schellekens, H., Klinger, E., Mhlebach, S., et al. “The therapeutic equivalence of complex drugs.” Regul Toxicol Pharmacol, 59(2011): 176–183.
W orld Health Organization. The prevalence of anemia in women: a tabulation of available information. Second edition. Geneva. WHO (1992). [http:// apps.who.int/iris/bitstream/10665/58994/1/WHO_MCH_ MSM_92.2.pdf], last accessed Sept 9, 2015.
W orld Health Organization. The World Health Report. 22. Screening for Iron Deficiency Anemia – Including Iron Prophilaxis. Recommendation. Geneva. WHO (1998). [http://www.ncbi.nlm.nih.gov/books/ NBK15471/?report=reader], last accessed Sept 9, 2015.
T oblli, J.E., Cao, G., Giani, J., et al. “Different effects of European iron sucrose similar preparations and originator iron sucrose on nitrosative stress, apoptosis, oxidative stress, biochemical and inflammatory markers in rats.” XLVIII ERA EDTA Congress (2011).
Van Wyck, D.B., et al. “A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis dependent CKD.” Kidney Int, 68(2005): 2846–2856.
Yip, R. “Iron deficiency: contemporary scientific issues and international programmatic approaches.” Journal of Nutrition Bethesda, 85 (Vol. 124) (1994): 1479–1490.